Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

Nov 25, 2020

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced

Nov 16, 2020

Anpac Bio Announces Appointment of New Independent Director

SAN JOSE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that Professor Jianhua Shao has been appointed as an independent

Nov 10, 2020

AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing

SAN JOSE, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has completed an FDA EUA- SARS-CoV-2 (COVID-19)

Stock Quote

Change

Volume

52 Week High

52 Week Low

Dec 1, 2020 10:36 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

AnPac Bio First Six Months 2020 Financial Results

Sep 10, 2020 at 8:00 AM EDT

View Webcast

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information